无法中和HIV-1原始分离株的HIV-1MN重组gp120疫苗血清，不会拮抗来自受感染个体的抗体的中和作用。 - Suppr

Suppr

超能文献

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.

作者信息

Wrin T, Nunberg J H

出版信息

AIDS. 1994 Nov;8(11):1622-3. doi: 10.1097/00002030-199411000-00017.

DOI:10.1097/00002030-199411000-00017

PMID:7848602

Abstract

摘要

相似文献

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.无法中和HIV-1原始分离株的HIV-1MN重组gp120疫苗血清，不会拮抗来自受感染个体的抗体的中和作用。

AIDS. 1994 Nov;8(11):1622-3. doi: 10.1097/00002030-199411000-00017.

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.由HIV-1MN重组糖蛋白120疫苗增强的HIV-1MN重组糖蛋白160疫苗诱导的细胞免疫和体液免疫。美国国立过敏与传染病研究所艾滋病疫苗评估小组。

AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32. doi: 10.1089/088922299311547.

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.用表达膜锚定糖蛋白120的重组金丝雀痘病毒载体进行免疫，随后用糖蛋白160加强免疫，无法产生中和1型人类免疫缺陷病毒R5初级分离株的抗体。

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35. doi: 10.1089/088922200750054756.

Antibodies from HIV-positive and AIDS patients bind to an HIV envelope multivalent vaccine.来自HIV阳性患者和艾滋病患者的抗体与一种HIV包膜多价疫苗结合。

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):317-24. doi: 10.1097/00126334-199912010-00001.

Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.用源自一株使用CCR5/CXCR4的1型人类免疫缺陷病毒分离株的单体重组gp120构建体免疫健康志愿者后产生的抗体库与自然感染个体的血清进行比较。

J Virol. 1999 Feb;73(2):1740-5. doi: 10.1128/JVI.73.2.1740-1745.1999.

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.一种用于人类的人类免疫缺陷病毒初免-加强免疫方案可诱导产生具有不同分支间交叉反应性并能中和多种X4、R5和双嗜性B和C分支主要分离株的抗体。

J Virol. 2000 Nov;74(21):10025-33. doi: 10.1128/jvi.74.21.10025-10033.2000.

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.重组人单克隆抗体对HIV-1原始分离株的高效中和作用。

Science. 1994 Nov 11;266(5187):1024-7. doi: 10.1126/science.7973652.

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.由IIIB和MN重组gp120疫苗诱导产生的针对天然人类免疫缺陷病毒1型包膜糖蛋白的抗体。美国国立过敏与传染病研究所艾滋病疫苗评估小组。

Clin Diagn Lab Immunol. 1996 Jul;3(4):378-86. doi: 10.1128/cdli.3.4.378-386.1996.

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.MN和IIIB重组糖蛋白120疫苗诱导产生针对1型人类免疫缺陷病毒原始分离株天然包膜糖蛋白的结合抗体。美国国立过敏和传染病研究所艾滋病疫苗评估小组。

AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):921-30. doi: 10.1089/088922299310638.

High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.非洲和美洲血清中针对HIV-1MN主要中和决定簇gp120 V3区域的抗体高流行率。

AIDS Res Hum Retroviruses. 1991 Oct;7(10):831-8. doi: 10.1089/aid.1991.7.831.

引用本文的文献

Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.酵母糖蛋白引发的抗体可识别HIV-1病毒体，并有效中和具有高甘露糖N-聚糖的病毒体。

Vaccine. 2015 Sep 22;33(39):5140-7. doi: 10.1016/j.vaccine.2015.08.012. Epub 2015 Aug 13.

Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.在人源 CD4+/CXCR4+/CCR5+T 淋巴母细胞系测定系统中检测 HIV-1 中和抗体。

PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.

HIV-1 neutralizing antibodies: understanding nature's pathways.HIV-1 中和抗体：理解自然途径。

Immunol Rev. 2013 Jul;254(1):225-44. doi: 10.1111/imr.12075.

Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.包含猿猴免疫缺陷病毒 SIVsmE660 分离株和疫苗挑战株的病毒中和敏感性的异质性。

J Virol. 2013 May;87(10):5477-92. doi: 10.1128/JVI.03419-12. Epub 2013 Mar 6.

Neutralizing antibodies to HIV-1 induced by immunization.免疫诱导的抗 HIV-1 中和抗体。

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827.

The design and evaluation of HIV-1 vaccines.HIV-1 疫苗的设计与评估。

AIDS. 2012 Jun 19;26(10):1293-302. doi: 10.1097/QAD.0b013e32835474d2.

Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques.恒河猴体内 SIVsmE660 克隆的连续进化和对中和抗体的逃逸。

J Virol. 2012 Aug;86(16):8835-47. doi: 10.1128/JVI.00923-12. Epub 2012 Jun 13.

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.设计引发 HIV-1 广谱中和抗体的疫苗的合理性。

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.通过基于 HA/gp41 嵌合蛋白的 DNA 和 VLP 疫苗诱导针对 HIV 包膜蛋白 MPER 的中和抗体。

PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.

Structure-based vaccine design in HIV: blind men and the elephant?基于结构的 HIV 疫苗设计：盲人摸象？

Curr Pharm Des. 2010;16(33):3744-53. doi: 10.2174/138161210794079173.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验